title: [Therapeutic Options in Vitreomacular Traction With or Without a Macular Hole].
abstract: Treatment is usually indicated for symptomatic vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) and without spontaneous resolution. Ultrastructural parameters are evaluated by SD-OCT, in order to classify the vitreoretinal interface and to estimate the success rate of treatment. The resolution rate after therapy with intravitreal Jetrea® (Ocriplasmin) is high (up to 70 %) in patients with symptomatic focal vitreomacular traction (≤ 1500 µm) with or without a macular hole (≤ 250 µm) and with no epiretinal membrane (ERM), but depends on the exact baseline analysis. All other patients with idiopathic traction retinopathy should be treated by minimal invasive pars plana vitrectomy (MIVI). Vitreoretinal surgery effectively removes traction and gives a high closure rate of a full thickness macular hole (FTMH, 90 to 100 %). It is now a very safe procedure with few side effects. Despite a low risk profile (cataract, retinal tear etc.) the indication for surgery needs to take the safety profile into account. Therefore vitrectomy is only indicated in symptomatic patients complaining of blurred vision, VA reduction and metamorphopsia. Vitrectomy is also indicated in patients whose treatment by pharmacologic vitreolysis has failed.
authors.affiliation: Augenklinik, Klinikum rechts der Isar, Technische Universität München.
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.affiliation: Augenklinik, Klinikum rechts der Isar, Technische Universität München.
authors.forename: S
authors.initials: S
authors.lastname: Abraham
authors.affiliation: Augenklinik, Klinikum rechts der Isar, Technische Universität München.
authors.forename: C
authors.initials: C
authors.lastname: Frank
authors.affiliation: Augenklinik, Klinikum rechts der Isar, Technische Universität München.
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
authors.affiliation: Augenklinik, Klinikum rechts der Isar, Technische Universität München.
authors.forename: N
authors.initials: N
authors.lastname: Feucht
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D005341:Fibrinolysin / Q000008:administration & dosage; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D010446:Peptide Fragments / Q000008:administration & dosage; D012163:Retinal Detachment / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D012167:Retinal Perforations / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D000267:Tissue Adhesions / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014821:Vitrectomy / Q000379:methods; D020255:Vitreous Detachment / Q000150:complications / Q000473:pathology / Q000628:therapy*
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin